Last Updated: 2026-03-13 PT
Despite significant advances in amyloid-targeting immunotherapies for Alzheimer's disease, clinical trials have demonstrated only modest efficacy, with disease progression slowing by approximately 27% at best. This knowledge gap represents a critical area for research and therapeutic development.[1][2]
Lecanemab received accelerated approval from the FDA in January 2023 and full approval in July 2023. The Phase 3 CLARITY-AD trial demonstrated:
Donanemab, developed by Eli Lilly, showed in the Phase 3 TRAILBLAZER-ALZ 2 trial:
Aducanumab (Aduhelm) received accelerated approval in 2021 based on amyloid plaque reduction, though the EMERGE trial showed 22% slowing of clinical decline at high dose.[3]
Most trials enroll patients with established amyloid pathology, potentially after significant neuronal damage has already occurred. The amyloid cascade hypothesis suggests that amyloid accumulation begins 15-20 years before clinical symptoms appear.[4][5]
Even with successful plaque removal, existing tau pathology and neurodegeneration continue to progress. Amyloid removal may not reverse damage already present.[6]
Alzheimer's disease involves multiple parallel pathways beyond amyloid:
Some patients show cognitive decline despite amyloid clearance, suggesting significant amyloid-independent disease mechanisms.[11]
Even with amyloid removal, pre-existing tau pathology continues to spread through connected neural networks. Tau accumulation correlates more strongly with cognitive decline than amyloid.[7:1][12]
Synaptic dysfunction occurs early and may be only partially reversible. Postsynaptic receptors and neuronal connectivity may be permanently impaired.[9:1]
Microglial activation and chronic neuroinflammation persist even after amyloid removal. The innate immune response may drive neurodegeneration independently of amyloid. TREM2 variants significantly modify Alzheimer's risk, highlighting the importance of microglial pathways.[8:1][13]
van Dyck et al. Lecanemab in Early Alzheimer's Disease. The New England Journal of Medicine. 2023. ↩︎ ↩︎
Sims et al. Donanemab in Early Alzheimer's Disease. The New England Journal of Medicine. 2023. ↩︎ ↩︎
Budd Haeberlein et al. Aducanumab in Early Alzheimer's Disease. Alzheimer's & Dementia. 2022. ↩︎
Jack et al. Hypothetical Model of Dynamic Biomarkers in Alzheimer's Disease. Alzheimer's & Dementia. 2010. ↩︎ ↩︎
Bateman et al. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. The New England Journal of Medicine. 2012. ↩︎
Karran & De Strooper, The Amyloid Hypothesis in Alzheimer Disease. Nature Reviews Disease Primers. 2023. ↩︎
Hansson et al. Tau Pathology in Alzheimer's Disease. Nature Reviews Neurology. 2019. ↩︎ ↩︎
Heneka et al. [Neuroinflammation in Alzheimer's Disease](https://doi.org/10.1016/S1474-4422(15). The Lancet Neurology. 2015. ↩︎ ↩︎
Tkachev et al. Synaptic Proteome in Alzheimer's Disease. Neurobiology of Aging. 2020. ↩︎ ↩︎
van Veluw et al. Cerebral Amyloid Angiopathy. Nature Reviews Neurology. 2020. ↩︎ ↩︎
Poirier et al. Amyloid-Independent Neurodegeneration in Alzheimer's Disease. Neurobiology of Aging. 2023. ↩︎
Jucker & Duyckaerts, The Spread of Tau Pathology. Acta Neuropathologica. 2023. ↩︎
Deczkowska et al. TREM2 as a Therapeutic Target. Science. 2018. ↩︎ ↩︎
Mintun et al. Combination Therapy for Alzheimer's Disease. Alzheimer's & Dementia. 2023. ↩︎ ↩︎
Zhou et al. Complement-Mediated Synaptic Loss in Alzheimer's Disease. Nature Medicine. 2024. ↩︎